Boltz and Bristol Myers Squibb agree to deploy Boltz biomolecular models for drug discovery

Boltz PBC announced an agreement with Bristol Myers Squibb to deploy the Boltz platform and build custom models on BMS's NVIDIA DGX SuperPOD infrastructure, expanding researchers' access to biomolecular AI (October 21, 2026).